M&T Bank’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

M&T Bank’s Portfolio CNCE Stock Details CNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-377,586	Closed	-$4.77M	–	1756
2020 Q4	$4.77M	Buy	+377,586	New	+$4.3M	0.02%	378

Other funds holding CNCE

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

M&T Bank's CNCE Position: Q1 2021 in Review

M&T Bank sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q1 2021, closing a stake of 377,586 shares — an estimated $4.77M sold.

M&T Bank first reported a position in CNCE in Q4 2020 and held it in 1 quarter. The position peaked at $4.77M in Q4 2020. 91 funds tracked by Wall St. Rank hold CNCE as of Q1 2021.

M&T Bank reported no remaining Concert Pharmaceuticals, Inc. position as of Q1 2021 after selling out during the quarter.
M&T Bank sold 377,586 Concert Pharmaceuticals, Inc. shares in Q1 2021, an estimated $4.77M.
M&T Bank first reported a position in Concert Pharmaceuticals, Inc. in Q4 2020 and held it in 1 quarter.
M&T Bank's Concert Pharmaceuticals, Inc. position peaked at $4.77M in Q4 2020.
91 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q1 2021.

Based on M&T Bank's 13F filing for Q1 2021, filed 6 May 2021.